The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose

Metabolism: Clinical and Experimental
S KarunakaranR R Holman

Abstract

Self-referred subjects (N = 227) thought to be at increased risk of developing diabetes who had fasting plasma glucose (FPG) values in the range of 5.5 to 7.7 mmol.L-1 on two consecutive occasions 2 weeks apart were randomized to sulfonylurea therapy (gliclazide, < or = 160 mg.d-1) or to a control group allocated either to double-blind placebo or to no tablets. Subjects were randomly allocated also to reinforced or basic healthy-living advice in a factorial design. A total of 201 subjects have been evaluated for 1 year in three English and two French hospital outpatient centers. Those allocated to sulfonylurea had a significant (P < .001) reduction in median FPG compared with the control group (6.0 mmol.L-1 to 5.6 mmol.L-1, P < .001, v 6.0 mmol.L-1 to 6.0 mmol.L-1, NS). Median hemoglobin A1c (HbA1c) also improved (P < .0002; 5.8% to 5.6%, P < .001, v 5.7% to 5.6%, NS), as did mean beta-cell function (62% to 70%, P < .01, v 62% to 61%, NS). Mean body weight was unchanged in subjects allocated to sulfonylurea (81.7 kg to 82.4 kg, NS), but decreased in the control group (81.6 kg to 80.4 kg, P < .01). More subjects in the sulfonylurea group versus the control group reported one or more minor symptoms of hypoglycemia over 1 year (50...Continue Reading

Citations

Jan 22, 2010·The Cochrane Database of Systematic Reviews·Asbjørn Hróbjartsson, Peter C Gøtzsche
May 24, 2001·The New England Journal of Medicine·A Hróbjartsson, P C Gøtzsche
Mar 17, 2010·The New England Journal of Medicine·Rury R HolmanRobert M Califf
Aug 17, 2011·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Erik Snorre ØfjordTrond Jenssen
Mar 31, 2004·Journal of Clinical Pharmacology·L Michael Prisant
Mar 25, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·O J PhungC I Coleman
Oct 19, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·M IncaniM G Baroni
Dec 28, 2010·Primary Care Diabetes·Barbara WesterhausGuillermo E Umpierrez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.